Skip to main content

Neuromodulation

Neuromodulation procedures for OAB, urgency urinary incontinence, retention, and fecal incontinence now live on procedure-specific pages:

PageUse it for
Sacral NeuromodulationImplanted S3 lead + pulse generator systems, test phase, programming, device revisions
Percutaneous Nerve EvaluationOffice-based temporary S3 test stimulation before permanent SNM implantation
Percutaneous Tibial Nerve StimulationOffice PTNS, transcutaneous alternative and maintenance counseling
Implantable Tibial Nerve StimulationDistinct lower-leg implants, power/programming models and device-specific MRI/safety review
Pudendal NeuromodulationInvestigational implanted pudendal-lead stimulation studied for urinary, bowel, and pelvic-pain indications; evidence remains too limited for an established OAB or retention pathway.[7]

How to Use This Hub​

Neuromodulation is a family of treatments that share electrical modulation of bladder, bowel, pelvic-floor and afferent sensory circuits. The operations differ sharply in invasiveness, maintenance burden, reversibility and patient selection.

Clinical problemMain neuromodulation option
Urgency urinary incontinence / OABPTNS, implantable tibial stimulation or SNM according to preference and eligibility. The AUA/SUFU 2024 guideline recommends SNM, PTNS and/or intradetrusor botulinum toxin (a non-neuromodulation option) after inadequate response to or intolerable effects from pharmacotherapy or behavioral therapy [1]
Non-obstructive urinary retentionAfter excluding obstruction and addressing conservative options, consider SNM. The EAU 2026 female LUTS guideline recommends offering SNM to women with underactive bladder refractory to conservative management .[2] For men with detrusor underactivity and no benign prostatic obstruction, the EAU 2026 male LUTS guideline recommends offering an SNM test phase .[8]
Fecal incontinenceThe 2023 ASCRS guideline says SNM may be considered a first-line surgical option with or without sphincter defects (Conditional; low-quality evidence).[9] CONFIDeNT and NOTABLe did not meet their prespecified primary endpoints for PTNS versus sham.[3][4]
Patient wants the least invasive optionPTNS / TTNS, accepting maintenance burden
Patient wants implanted therapySNM after a successful test phase, or an appropriately indicated implantable tibial device without an SNM-style test phase. A 2026 sham-controlled Intibia trial found greater patient-reported improvement with active stimulation at three months (29.2% versus 13.4%, secondary QoL analysis); the sham arm then crossed over.[10] In Revi's single-arm cohort, 77/97 two-year completers (151 women implanted) met a ≥50% reduction in UUI episodes, but head-to-head efficacy and durability comparisons with SNM remain unavailable.[11][6]

Key Distinctions​

  • SNM targets the S3 sacral nerve root with an implanted lead and pulse generator. It requires a test phase, device programming, and long-term device surveillance.
  • PNE is not definitive treatment. It is a temporary screening procedure used to decide whether permanent SNM implantation is justified.
  • PTNS stimulates the posterior tibial nerve, usually in the office, and avoids an implanted sacral device but requires induction and maintenance sessions.
  • Pudendal nerve stimulation is an investigational peripheral target for refractory urgency-frequency, urgency incontinence and nonobstructive retention, not an established alternative to SNM. In a small single-blind, randomized crossover trial (n = 30) that implanted both an S3 lead and a pudendal lead and tested each for 7 days, 24 of 30 patients responded; overall symptom improvement was 63% with pudendal stimulation versus 46% with sacral stimulation (P = 0.02), and among the 24 responders, 79.2% chose the pudendal lead as superior.[5] For lead placement, FDA status and the separate pudendal-neuralgia literature, see Pudendal Neuromodulation.
  • Implantable tibial systems stimulate near the ankle with distinct batteries or wearables and FDA indications; an individual implant's MRI and other device precautions must be checked separately. The AUA/SUFU 2024 guideline states that clinicians may offer minimally invasive therapies without requiring trials of behavioral, non-invasive or pharmacologic management . AUA/SUFU permits flexible sequencing.[1]

Practical Counseling​

Preoperative counseling asks whether the patient can accept the maintenance model. Some patients prefer PTNS office visits to an implant, and others prefer implanted SNM to repeated visits.[12] In a 23-patient retrospective series, 14 of 22 patients with poor PTNS response had a successful subsequent SNM test.[12] The target and stimulation strategy differ.

For device hardware, see the neuromodulation-device pages under Tools / Biomaterials, including eCoin, Axonics, and Medtronic InterStim profiles.

References​

1. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985

2. European Association of Urology. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms, 2026, section 4.4.4.c.1 (sacral nerve stimulation). uroweb.org

3. Knowles CH, Horrocks EJ, Bremner SA, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. Lancet. 2015;386(10004):1640-1648. doi:10.1016/S0140-6736(15)60314-2

4. Zyczynski HM, Richter HE, Sung VW, et al. Percutaneous tibial nerve stimulation vs sham stimulation for fecal incontinence in women: NeurOmodulaTion for Accidental Bowel Leakage randomized clinical trial. Am J Gastroenterol. 2022;117(4):654-667. doi:10.14309/ajg.0000000000001605

5. Peters KM, Feber KM, Bennett RC. Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn. 2005;24(7):643-7. doi:10.1002/nau.20174

6. Amundsen CL, Sutherland SE, Kielb SJ, Dmochowski RR. "Sacral and implantable tibial neuromodulation for the management of overactive bladder: a systematic review and meta-analysis." Adv Ther. 2025;42(1):10-35. doi:10.1007/s12325-024-03019-0

7. Herroelen S, Knowles C, Kerrigan-Smith J, Noone T, Denison T, De Wachter S. "Pudendal nerve stimulation for treatment of lower urinary tract symptoms: a systematic review of safety, technical feasibility and clinical efficacy." Continence. 2024;11:101685. doi:10.1016/j.cont.2024.101685

8. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS). EAU Guidelines Office; 2026. Full guideline

9. Bordeianou LG, Thorsen AJ, Keller DS, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence." Dis Colon Rectum. 2023;66(5):647-661. doi:10.1097/DCR.0000000000002776

10. Mangel J, Miller K, Erickson T, Dieter A, Roovers JP, Matthews CA. "Randomized, Sham-Controlled, Double-Blind Trial of the Intibia System in Urge Urinary Incontinence: Quality-of-Life Outcomes." Int Urogynecol J. 2026. doi:10.1007/s00192-026-06636-1

11. Heesakkers JPFA, Toozs-Hobson P, Sutherland SES, et al. "Two-Year Efficacy and Safety Outcomes of the Pivotal OASIS Study Using the Revi System for Treatment of Urgency Urinary Incontinence." J Urol. 2025;213(3):323-332. doi:10.1097/JU.0000000000004328

12. Kapriniotis K, Jenks J, Toia B, et al. "Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation?" Neurourol Urodyn. 2022;41(5):1172-1176. doi:10.1002/nau.24944